WUXI BIO (02269): Miao Jingwen appointed as non-executive director.
Wu Yibing, Ph.D., has resigned as of November 20, 2024, in an announcement from WuXi Biologics (02269).
WUXI BIO (02269) announces that, effective from November 20, 2024, Dr. Wu Yibing has resigned as a non-executive director and member of the Board's decision-making committee to dedicate more time to other personal matters. Ms. Miao Jingwen has been appointed as a non-executive director and member of the decision-making committee.
Related Articles
New Stock News | Love Core Element GMTEight passes the Hong Kong Stock Exchange hearing, becoming the world's largest provider of high-end vision edge AI inference chips.
New stock preview | Financial mirror fracture: decoding the growth logic paradox behind the Shanghai Jizhi "smart manufacturing" narrative.
New Stock Update | Wuxi Lead Intelligent Equipment (300450.SZ) held a hearing at the Hong Kong Stock Exchange, claiming to be the second largest supplier of new energy intelligent equipment in the world with a market share of 2.9%.
New Stock News | Love Core Element GMTEight passes the Hong Kong Stock Exchange hearing, becoming the world's largest provider of high-end vision edge AI inference chips.
New stock preview | Financial mirror fracture: decoding the growth logic paradox behind the Shanghai Jizhi "smart manufacturing" narrative.
New Stock Update | Wuxi Lead Intelligent Equipment (300450.SZ) held a hearing at the Hong Kong Stock Exchange, claiming to be the second largest supplier of new energy intelligent equipment in the world with a market share of 2.9%.
RECOMMEND
Paul Chan Says Hong Kong Has Licensed 11 Virtual Asset Exchanges, Stablecoin Licenses Expected Later This Year
22/01/2026
Ministry Of Finance And Other Departments Introduce Comprehensive Fiscal And Financial Policies To Boost Domestic Demand
22/01/2026
Capital Migration: Five Years On, An In‑Depth Analysis Of China’s 11 High‑Growth Venture Capital Tracks In 2025
22/01/2026
